A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses.

There was also a slight trend of an increase noted in B cells, when PBMCs were stimulated with CEFT peptides and treated with avelumab, compared with the isotype control ( P= 0.06); there were no alterations noted in the frequency of NK cells, NK-T cells or Tregs, and the percentages of conventional dendritic cells, plasmacytoid dendritic cells and myeloid derived suppressor cells were too low at the end of the stimulation assay to be evaluated.

also in 4,078 other papers